Dec 29, 2008
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to...
426
Dec 12, 2007
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are...
351
Dec 8, 2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
Br J Haematol 2007 Jul Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Bart...
167
Dec 8, 2005
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With...
491
Dec 10, 2004
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after...
271
Dec 9, 2004
NCT00081939: UARK 2003-33, Total Therapy III
UARK 2003-33, Total Therapy III Total Therapy 3 The UARK 2003-33, Total Therapy III - There have been two previous Total Therapy studies...
257
Dec 14, 2000
Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999
Time Frame: August 1990 and August 1995 Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood; 1999 B Barlogie...
48